/PRNewswire/ The non-transfusion-dependent (NTD) form of β-thalassemia, an inherited blood disorder with impaired production of hemoglobin, is characterized.
/PRNewswire/ At the forefront of the fight against COVID-19, Integral Molecular s rapid Epitope Mapping technology is being used to pinpoint precise binding.
Share this article
Share this article
HONG KONG, June 10, 2021 /PRNewswire/ CBMG Holdings (or the Company ), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced early promising safety and efficacy results of C-CAR066, a novel second generation chimeric antigen receptor T (CAR-T) therapy targeting CD20 antigen in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) that has failed to an anti-CD19 CAR-T therapy. Patients who fail anti-CD19 CAR-T therapy generally have a dismal prognosis and are an important group with high unmet medical needs. This abstract was recently presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, China.
/PRNewswire/ A new study from researchers at Children s Hospital of Philadelphia (CHOP) and the University of Pennsylvania s Annenberg Public Policy Center.
/PRNewswire/ Ossianix, an antibody engineering company, and the University of Graz today announced the publication of a preclinical study that describes.